

Investor Webinar Invite

PainChek Limited (ASX: PCK) (“PainChek” or “the Company”) is pleased to invite shareholders and investors to attend an investor webinar, Lynx Discovery Series: Health Innovation.

The webinar will be held on Tuesday, 8 September 2026 at 12:00pm AEST.

Register via: https://us02web.zoom.us/webinar/register/WN_2ih3cNIDQtp7uBl-szWTA#/registration

PainChek Non-Executive Director and Non-Executive Chair, Lil Bianchi, and Chief Executive Officer, Karen Holzberger, will present an update on the Company’s progress in scaling its AI-powered pain assessment platform internationally, including the significant growth opportunity emerging in the United States.

PainChek is an AI-powered pain assessment solution that uses facial analysis and other clinical indicators to help identify and assess pain, including in people who cannot reliably self-report their pain.

The presentation will focus on PainChek’s recent commercial progress and strategy for scaling its platform across international markets. Ms Bianchi and Ms Holzberger will discuss the Company’s growing base of implemented licences and recurring revenue, its continued expansion across established markets, and its strategy for the United States following FDA De Novo clearance, which has established a pathway into the world’s largest healthcare market.

The presentation will also cover PainChek’s progress in building its US commercial presence, including its initial focus on long-term care, skilled nursing and memory care, and the opportunity to convert early deployments and commercial relationships into broader adoption.

Following the presentation, Ms Bianchi and Ms Holzberger will participate in a moderated Q&A session, providing investors with the opportunity to put questions directly to management.

Investors are encouraged to register in advance using the link above. Questions can be submitted during the webinar through the Q&A function.

A recording of the webinar will be made available following the event.

This announcement has been authorised for release by the Board of PainChek Limited.

ENDS

ASX ANNOUNCEMENT
3 September 2026



For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

David Tasker
Chapter One Advisors
dtasker@chapteroneadvisors.com.au
+61 433 112 936

About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, the United Kingdom and most recently FDA De Novo clearance in the United States.

PainChek® has contracts with over 2,000 aged care facilities, with more than 22,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

PainChek® is setting a new benchmark for pain assessment. Being the first TGA-approved and FDA-cleared medical device for pain assessment, PainChek® combines AI and Human Intelligence to detect pain in people who cannot reliably self-report.

For more information, visit: <https://painchek.com>